Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022.

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Gerstein HC, Colhoun HM, Dagenais GR, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. Liraglutide and cardiovascular outcomes in type 2 diabetes. Marso SP, Daniels GH, Brown-Frandsen K, et al. The results suggest that switching to SG may be a useful option in patients experiencing inadequate glycemic control with DG. Switching from 0.75 mg DG to 0.5 mg SG in patients with T2DM improved glycemic variability, mean glycemic index, and daily variability without increasing the hypoglycemic index. In contrast, SG had no effect on the time below range and minimum sensor glucose compared to DG. Regarding the secondary outcome measures, standard deviation of glucose, average sensor glucose, time above range, maximum sensor glucose, interquartile range, SD of glucose during the nocturnal period (0000–0559), and average nocturnal sensor glucose (0000–0559) were significantly better with SG than DG. Time in range was significantly better with SG than with DG, which was the main outcome measure. All patients wore the professional CGM twice, once while receiving DG and once when the SG dose was increased to 0.5 mg/week. The study subjects were 12 T2DM patients with HbA1c ≥ 7.0% on treatment with 0.75 mg/week DG for at least 24 weeks. This study compared the efficacy and safety of DG and SG using professional CGM in 12 patients attending our outpatient with poorly controlled type 2 diabetes mellitus (T2DM) while using GLP-1RA. However, little is known about the differences between these two compounds in clinical practice in Japan. Currently, the most frequently prescribed once weekly glucagon-like peptide-1 receptor agonists (GLP-1RA) in Japan are dulaglutide (DG) and semaglutide (SG).

Download glucod